Five Commercial Immunoassays for SARS-CoV-2 Antibody Determination and Their Comparison and Correlation with the Virus Neutralization Test

0544580 - ÚI 2022 CH eng J - Článek v odborném periodiku
Šimánek, V. - Pecen, Ladislav - Krátká, Z. - Fürst, T. - Řezáčková, H. - Topolčan, O. - Fajfrlík, K. - Sedláček, D. - Šín, R. - Pazdiora, P. - Zelená, H. - Slouka, D. - Kučera, R.
Five Commercial Immunoassays for SARS-CoV-2 Antibody Determination and Their Comparison and Correlation with the Virus Neutralization Test.
Diagnostics. Roč. 11, č. 4 (2021), č. článku 593. E-ISSN 2075-4418
Klíčová slova: SARS-CoV-2 * antibody * immunoassay * nucleocapsid protein * serological diagnostics * spike protein * virus neutralization test
Impakt faktor: 3.992, rok: 2021
Způsob publikování: Open access

There is an ongoing debate as to whether SARS-CoV-2 antibodies can be found in patients who have recovered from COVID-19 disease. Currently, there is no consensus on whether the antibodies, if present, are protective. Our regular measurements of SARS-CoV-2 antibodies, starting in July 2020, have provided us with the opportunity of becoming acquainted with the five different immunoassays. A total of 149 patients were enrolled in our study. We measured the samples using each immunoassay, then performing a virus neutralization test and comparing the results of SARS-CoV-2 antibodies with this test. We observed that the production of neutralizing antibodies is age-dependent. Elderly patients have a higher proportion of high neutralizing titers than young patients. Based on our results, and in combination with the literature findings, we can conclude that the serological SARS-CoV-2 antibody measurement is a helpful tool in the fight against COVID-19. The assays can provide information about the patient's previous contact with the virus. Anti-spike protein assays correlate well with the virus neutralization test and can be used in the screening of potential convalescent plasma donors.
Trvalý link: http://hdl.handle.net/11104/0321423